Latest (October 16, 2026): retatrutide's phase 3 results are now peer-reviewed; Medicare Open Enrollment runs October 15 to December 7; FDA posted warning letters to two websites selling unapproved semaglutide; and FDA's October 1 page update bars retatrutide and cagrilintide from compounding. 13 dated entries below, newest first.
Each entry has a date, a short summary, what it means for you, and its source. "Confirmed" means we read a primary source; "reported" means press coverage only.
October 16, 2026 — Retatrutide phase 3 papers: what TRIUMPH-1 and TRIUMPH-2 showed
Our analysis of the two retatrutide phase 3 trials published on September 29, 2026 (NEJM and The Lancet): weight change of −17.6% to −25.0% at 80 weeks in adults without diabetes, and −11.9% to −18.8% in adults with type 2 diabetes, by treatment-regimen estimand. Retatrutide is investigational and not FDA-approved.
What it means for you: Nothing to buy yet. Products sold online as "retatrutide" are not the trial drug.
Status: confirmed · Read the analysis
October 15, 2026 — Medicare Open Enrollment opens; Lilly confirms Q3 results date
Medicare Open Enrollment runs October 15 to December 7, 2026. Lilly says it will report third-quarter 2026 results on October 29, 2026; Foundayo reduced self-pay prices and the Wegovy $199 starter offer run through December 31, 2026.
What it means for you: If you are on Medicare, check how your Part D plan treats GLP-1s; the GLP-1 Bridge covers only Foundayo, Wegovy and the Zepbound KwikPen, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for it.
Status: confirmed · Medicare.gov: joining a plan · CMS: Medicare GLP-1 Bridge
October 14, 2026 — JAMA Network Open: Reddit posts on gray-market retatrutide
A research letter analyzed 148,640 Reddit posts and comments; among self-reported users, the most common complaints were increased appetite (17.1%), fatigue (15.2%) and increased heart rate (4.8%). The authors call the findings hypothesis-generating. A JAMA news feature (October 9) reported 21 FDA warning letters to retatrutide sellers since December 2024.
What it means for you: Do not inject products sold as "research peptides". Report reactions to FDA MedWatch.
Status: confirmed · JAMA Network Open
October 12, 2026 — Ozari Health lists compounded tirzepatide at $125 a month
Ozari Health announced compounded tirzepatide at $125 a month at every dose ($86 semaglutide) and a second plan, in paid press releases of October 6 and 12. We have not added it to our price index.
What it means for you: Treat new entrants like any program: check the pharmacy, the billing basis and the cancellation terms first.
Status: reported
October 6, 2026 — FDA posts warning letters to two websites selling unapproved semaglutide
FDA posted warning letters 737806 (onlinegenericmedicine.com, dated September 23) and 737810 (cheapmedicineshop.com, dated September 24) for unapproved injectable semaglutide.
What it means for you: Buy only through a licensed U.S. pharmacy with a prescription.
Status: confirmed · FDA warning letters
October 1, 2026 — FDA updates its page on unapproved GLP-1 drugs
FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page, current as of October 1, 2026, says retatrutide and cagrilintide cannot be used in compounding under federal law and gives a 28-day discard rule for compounded multi-dose GLP-1 vials.
What it means for you: Check the beyond-use date on your vial and discard it on time.
Status: confirmed · FDA page
October 1, 2026 — Rhode Island Medicaid ends coverage of GLP-1s prescribed only for weight loss
Rhode Island Medicaid stopped covering GLP-1 drugs prescribed solely for weight loss from October 1, 2026; coverage for diabetes continues.
What it means for you: Rhode Island Medicaid members using a GLP-1 for weight loss should ask their clinician about alternatives.
Status: confirmed
September 30, 2026 — ACHIEVE-4: orforglipron (Foundayo) meets cardiovascular safety goal in type 2 diabetes
In 2,749 adults with type 2 diabetes and heart or kidney disease, major cardiovascular events occurred in 4.2% on orforglipron vs 5.0% on insulin glargine over a median of about two years (HR 0.84), meeting non-inferiority (The Lancet). Gastrointestinal side effects were 62.1% vs 14.2%.
What it means for you: Foundayo is FDA-approved for weight management; a U.S. type 2 diabetes approval had not been found as of October 16, 2026.
Status: confirmed · PubMed
September 29, 2026 — Retatrutide TRIUMPH-1 and TRIUMPH-2 published
NEJM and The Lancet published the first retatrutide phase 3 trials. Lilly plans to file for approval in the first quarter of 2027.
What it means for you: See our full analysis above.
Status: confirmed · TRIUMPH-1 on PubMed
September 29, 2026 — CMS: Medicare GLP-1 Bridge runs through December 31, 2027
CMS's BALANCE Model page carries an FAQ about "the BALANCE Model not launching in Medicare in 2027" (page modified September 29, 2026). The Medicare GLP-1 Bridge — a $50 copay for eligible Part D enrollees — runs from July 1, 2026 to December 31, 2027.
What it means for you: Bridge eligibility is narrow; check Medicare.gov before you count on it.
Status: confirmed · CMS BALANCE Model
September 22, 2026 — FDA warning letter to Empower Pharmacy (738238)
FDA's warning letter to Empower Pharmacy, dated September 18 and posted September 22, 2026, says its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin "appear to be essentially copies" of FDA-approved products and cites insanitary conditions.
What it means for you: If your prescription includes an added vitamin, ask your program which pharmacy fills it.
Status: confirmed · FDA letter
September 2, 2026 — Diabetes Care: oxycodone carried more severe GI events than hydrocodone in GLP-1 users
In 411,188 adults with type 2 diabetes on a GLP-1 drug, the 30-day risk of severe constipation, bowel obstruction or gastroparesis was 0.51% after starting oxycodone vs 0.35% with hydrocodone (RR 1.48).
What it means for you: If you need a pain medicine after a procedure, tell the prescriber you take a GLP-1.
Status: confirmed · PubMed
August 27, 2026 — FDA approves Mounjaro to reduce cardiovascular events in type 2 diabetes
FDA approved a new Mounjaro indication to reduce the risk of cardiovascular death, heart attack and stroke in adults with type 2 diabetes at high risk, based on SURPASS-CVOT, which showed non-inferiority to dulaglutide (HR 0.92). The Zepbound label's diabetic retinopathy warning was revised the same month.
What it means for you: The indication applies to brand Mounjaro, not to compounded tirzepatide.
Status: confirmed · openFDA label
Archive: May–July 2026 entries (not re-verified)
July 8, 2026 — UnitedHealthcare expands Wegovy CV coverage
UnitedHealthcare announced expansion of Wegovy coverage under the March 2024 FDA cardiovascular indication. Coverage criteria mirror SELECT enrollment: BMI ≥27 + established CVD (prior MI, ischemic or hemorrhagic stroke, or symptomatic PAD). Quest member benefits update expected mid-June. See UHC coverage page.
July 8, 2026 — Anthem BCBS adds Zepbound OSA coverage in 14 states
Anthem BCBS announced coverage of Zepbound for moderate-to-severe OSA in adults with BMI ≥30 across 14 state plans. Criteria: documented OSA diagnosis (AHI ≥15), failed PAP trial OR concurrent PAP use. See Anthem coverage page.